Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trialKausik K Ray, Shaun G Goodman, Corinne Hanotin et al.|The Lancet Diabetes & Endocrinology|2019Cited by 330
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolZeljko Reiner, Gregory G. Schwartz, Vera A. Bittner et al.|Journal of the American College of Cardiology|2021Cited by 143
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab TreatmentGregory G. Schwartz, Nicolas Danchin, Michael Szarek et al.|Diabetes Care|2021Cited by 39
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observationShaun G. Goodman, Ivan Pećin, Philippe Gabríel Steg et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2024Cited by 24
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMESPhilippe Gabríel Steg, Nikolaus Marx, Michael Szarek et al.|Circulation|2025Cited by 23